Nathan A. Pennell, MD, PhD, director of the Lung Cancer Medical Oncology Program at Taussig Cancer Institute at the Cleveland Clinic, emphasizes the importance of molecular testing before establishing a lung cancer treatment plan, particularly for nonsquamous non-small cell lung cancer (NSCLC) patients. Dr. Pennell recommends delaying immunotherapy until molecular testing is complete, as patients with oncogenic driver mutations may experience significant toxicity upon switching to a more targeted immunotherapy. Learn more by clicking here.